 HER-2,3
 targeted therapy,5
 [,10
 Carcinogenesis,2
 Cancer,11
 cyclophosphamide,2
 Breast cancer,3
Video-assisted thoracic surgery ,2
 Stereotactic radiotherapy,4
 lymph nodes,3
 angiogenesis,4
 lung tumor,2
cytology,3
5-dimethylthiazol-2-yl,2
Diagnosis,2
 prognostic factors,3
 pleural effusions,2
 Solitary pulmonary nodule,3
 hypersensitivity,2
 Non-small cell lung carcinoma,2
 video-assisted thoracic surgery ,5
 Polymorphism,2
Lung,2
 smoking,4
 poly,5
 Outcomes,4
 small cell lung carcinoma ,2
 elderly,2
 docetaxel,8
 Palladium,2
 K-ras mutation,2
 effusion,2
 ERK,4
 FEV,2
Diabetes,2
 chemoradiation,3
Chemoradiotherapy,2
 kidney cancer,2
 IKK,2
 reactive oxygen species,9
 actinomycin D,3
-dl-tryptophan,2
ERCC1,3
 bone scan,2
Lung cancer surgery,2
 brain metastases,4
 Radiation pneumonitis,5
 carboplatin,3
 Lung neoplasm,2
 OR,4
 monoclonal antibody,4
 COPD,4
 TRAIL,2
 Recurrence,7
 PARP,5
 hypoxemia,2
 immune escape,2
 immunotherapy,6
apoptosis,2
 Prognostic factors,6
cisplatin,2
 Lewis lung carcinoma,3
Minimally invasive surgery,2
 siRNA,9
 fibrosis,2
 Fluorescence in situ hybridization,2
 Tobacco,3
Fibrosis,2
 malignant pleural effusion,2
Early detection,2
 tumor necrosis factor-α,2
 N,2
 drug resistance,2
biomarkers,2
Malignant mesothelioma,2
 polymerase,3
 Nrf2,3
 Squamous cell carcinoma,4
 LOH,2
 Gene Regulation,2
3-[,2
 stereotactic body radiotherapy,2
 Tumor multidrug resistance,2
 LPS,2
 risk factors,2
 EMT,9
 epidermal growth factor receptor-tyrosine kinase inhibitor,2
 Prognosis,21
hetero,2
 Epidermal growth factor receptor,7
 Lobectomy,4
 morphology,2
 Di,2
 Nonsmall cell lung cancer,2
 Histology,2
 staging,10
Antiproliferative activity,2
 colon cancer,2
 paclitaxel,6
 Tyrosine kinase inhibitor,4
 small interfering RNA,3
 ECM,2
Oncology,2
 non-small cell,3
 Nanoparticles,2
Brain metastases,4
 melanoma,6
 tumor growth,3
Drug resistance,3
Complications,2
 Cancer bronchique,3
 segmentectomy,2
 cell invasion,2
 palliative care,6
 mRNA,3
 Telomerase,3
 TLR4,2
 Proton therapy,2
 Immunotherapy,5
 IFN,2
PET,4
MET,2
 TNF-α,5
 mouse model,3
Asthma,3
 HIF-1α,2
 Small cell carcinoma,2
 prostate cancer,3
 Sublobar resection,2
 LC3,2
 GSH,2
 EGFR mutation,4
 receptor tyrosine kinase,3
 ROC,4
Breast Cancer,3
 qPCR,2
 Ion beam therapy,2
 outcomes,2
 ETS,2
 DNA damage,4
Acute toxicity,2
 MMP,2
 hypoxia,4
 nasopharyngeal carcinoma,2
SCLC,11
 Protons,2
 nitric oxide,3
 PI3K,4
 neutropenia,2
 ASO,2
 minimally invasive surgery,3
 TLR,3
 Disparities,2
 GSK3β,2
Advanced lung cancer,2
Carboplatin,3
 Interstitial,2
 lung disease,2
Cisplatin,3
 oncology,3
 SCC,2
 MDM2,2
 Metastasectomy,2
 reticuloendothelial system,2
 Ogg1,2
Asbestos,3
 cell death,2
 Pleurectomy,4
 Radon,2
 Epidemiology,6
Computed tomography,4
5-diphenyltetrazolium bromide,2
Brain metastasis,4
 FEV1,3
EGFR-TKI,2
EMT,4
 small cell lung cancer ,2
 BMI,2
 SABR,3
 chromatin,2
 bronchoscopy,5
 prognostic factor,3
 Apoptosis,10
 lung metastasis,3
 Radiation,2
Biomarkers,4
 pleura,3
non-small cell lung cancer,3
 adjuvant chemotherapy,2
 cardiovascular disease,3
 cancer stem cell,3
 microRNAs,3
 EBV,2
 biomarker,5
 vasculitis,2
 interventional pulmonology,2
 phosphate buffered saline,2
Non-small cell lung cancer ,6
 interleukin-6,2
 Pleural effusion,3
 non-small cell lung cancer ,6
 glucose metabolism,2
Adults,2
ALK translocation,2
 biopsy,3
 Inflammation,2
 Pharmacokinetics,2
A549 cells,2
 integrins,2
 Pneumothorax,2
 Lung metastases,3
 FBS,2
 CYFRA 21-1,3
 PDGFR,2
 non-small cell lung carcinoma,6
 tumor-associated antigen,2
 mutation,6
 Chemotherapy,7
 apoptosis,18
 STAT3,4
NSCLC,32
 radiation,3
 stereotactic,2
 esophageal cancer,5
adjuvant chemotherapy,2
IMRT,2
 microRNA,7
 Lung metastasis,4
 Etoposide,2
18F-FDG PET,3
 neuroendocrine tumors,2
 Lymphoma,2
 mammalian target of rapamycin,3
 protein kinase C,2
 sunitinib,2
 incidence,3
 neoadjuvant chemotherapy,2
 Epigenetics,3
 Pleura,3
 macrophages,2
 GFP,2
 Lung Cancer,3
 malignant pleural mesothelioma,2
 sleeve lobectomy,2
 IL,3
 Antimicrobial activity,2
-2,2
 Malignant pleural mesothelioma,5
 poly ,2
 Fibrosis,2
 Prostate cancer,2
 Prostate,2
 Lung cancer surgery,3
 National Lung Screening Trial,2
 proliferation,5
 Tumor suppressor gene,2
 FDA,2
 thoracoscopy,4
 pleural metastasis,2
 Erlotinib,6
 Epithelial–mesenchymal transition,4
 fluorescent probes,2
 computed tomography,5
 HPV,3
 interstitial lung disease,3
 pathology,2
 Magnetic resonance imaging,2
 fractionation,2
 transforming growth factor,4
 Observational study,2
 cessation,2
 Technology,2
 endobronchial ultrasound,2
Lymph node dissection,2
 FAK,4
 systematic lymph node dissection,2
 mammary cancer,2
CTL,2
FDG,2
 bevacizumab,2
 epigenetics,5
 APC,2
 chloroquine,2
 Vaccine,2
Docetaxel,2
 KPS,2
 survival,15
 tumor necrosis factor α,2
 efficacy,2
2-hydroxypropyl,2
 Napsin A,2
adenocarcinoma,2
Apoptosis,11
Australia,2
 Non–small-cell lung cancer,3
 response,3
 Video-assisted thoracoscopic surgery,2
 stem cells,3
 mTOR,6
chemoradiation,2
Small cell lung cancer ,4
II,5
 Immunohistochemistry,6
Erlotinib,2
 Crizotinib,4
 prostate specific antigen,2
 Radiation dose,2
 messenger ribonucleic acid,2
 Lung cancer screening,2
 Targeted therapy,5
 WBRT,2
 neuroblastoma,2
 erlotinib,10
 cell cycle,7
 Lung adenocarcinoma,8
Carcinogenesis,2
 pneumonia,2
 phosphatidylinositol 3-kinase,2
 Gene expression,5
 Flexible bronchoscopy,2
Lung Neoplasms,2
Bevacizumab,3
Nonsmall cell lung cancer,2
2′,2
 chronic obstructive pulmonary disease,5
 FFPE,2
 Pneumonectomy,2
 Wedge resection,2
 CREB,2
,6131
 histone modification,2
 surgery,16
 N-,3
 Pneumonitis,2
ADP-ribose,4
 therapy,3
 Superior vena cava syndrome,2
 doxorubicin,4
 Cisplatin,4
 Colon cancer,2
 intensive care unit,2
 local control,2
 pulmonary metastases,3
 Tumor markers,2
 Stereotactic,3
 fetal bovine serum,2
 Thoracic surgery,3
 solid tumors,2
 superoxide dismutase,2
 Stereotactic ablative radiotherapy,5
 Mad2,2
 Malignant pleural effusion,2
IHC,2
 Stereotactic body radiotherapy,4
 Hyaluronic acid,2
7′-dichlorodihydrofluorescein diacetate,2
 FDG-PET,2
 rhabdomyosarcoma,3
 combination therapy,2
 vascular endothelial growth factor,6
 DNA repair,3
 Smoking,4
 radiation therapy,5
 gemcitabine,2
 Stereotactic radiosurgery,2
 IκBα,2
 volatile organic compounds,2
Lung neoplasms,5
DNA damage,2
 sarcoidosis,2
 tumor necrosis factor,2
 cancer stem cells,5
 FDG PET/CT,2
 Lung resection,2
 focal adhesion kinase,2
 oncogene,4
 IL-6,3
 Urinary bladder neoplasms,2
 PSA,3
 PLCO,2
 epidermal growth factor,2
 flow cytometry,3
 pain,5
 Malignant mesothelioma,2
Bronchoscopy,3
 fine needle aspiration,2
 Screening,4
 ERCC1,2
CT,5
Lobectomy,6
Video-assisted thoracoscopic surgery ,7
 Gene regulation,2
 CRC,3
 Mesothelioma,6
Colorectal cancer,3
Cancer,10
 Src,2
 Stage I,2
 prevention,4
 nanoparticles,3
 Oxidative stress,5
 extracellular matrix,3
VEGF,2
 Invasion,4
 pemetrexed,6
 mortality,7
 Lung,12
 Radiotherapy,11
 chronic obstructive pulmonary disease ,3
 EGF,2
 Squamous cell lung cancer,2
 Positron emission tomography,4
 Immunity,2
autofluorescence bronchoscopy,2
 Reactive oxygen species,3
 Liposome,3
 mesothelioma,4
 multidrug resistance,2
EGFR mutation,6
 RRM1,2
 bone metastasis,2
 OS,2
Adenocarcinoma,13
 NF-κB,9
 Small cell lung carcinoma,3
 clinical trial,4
 complete response,2
 Pemetrexed,7
 HIF-1,2
 odds ratio,4
 next-generation sequencing,2
 asthma,2
 pulmonary disease,2
 Non small cell lung cancer,5
Non-small cell lung cancer,11
 total lesion glycolysis,3
 Biomarkers,2
 Gefitinib,6
 Staging,3
 Radiofrequency ablation,3
DIGE,2
 Meta-analysis,5
 biodistribution,2
 mitogen-activated protein kinase,3
 microarray,7
 occupational exposure,3
 Prognostic factor,2
 Human,2
Antitumor activity,3
 histone deacetylase,3
 PTEN,3
 ifosfamide,2
 Proteomics,2
 RGD,2
 Pleural mesothelioma,2
 Lung neoplasms,9
 Palliative,2
 Guidelines,2
 HPMA,2
 cytology,2
 Antiproliferative activity,2
Autofluorescence bronchoscopy,2
 Neoplasms,3
 Trend,2
 immunocytochemistry,2
 TRF,2
 forced expiratory volume in 1 second,4
 Tyrosine kinase inhibitors,2
 LKB1,2
 acetylcholine,2
 diagnosis,5
 Feedback,2
 inflammation,4
 MALAT-1,2
 treatment,9
 cell proliferation,2
 Amino acids,2
 Length of stay,2
F-FDG-PET/CT,2
 E-cadherin,2
Biopsy,2
chemotherapy,2
 cancer susceptibility,2
 Incidence,3
 interferon,2
 Korea,2
 Cytotoxicity,9
 SBRT,8
 Computed tomography,3
 proteomics,2
 cohort studies,2
 Transforming growth factor beta1,2
 PET,13
 Proliferation,2
 computed tomography ,2
 BIC,2
 screening,7
 tumor hypoxia,3
 ROS,10
 lung adenocarcinoma,5
 renal cell carcinoma,3
Clinical trials,2
 Metabolomics,2
 mediastinum,2
 Metastasis,19
Carcinoma,3
 endoscopic ultrasound,3
 ROC curve,2
 Quality of life,4
 lung cancer,132
 Carcinoma,6
 epidermal growth factor receptor,17
 polymerase chain reaction,2
 migration,3
 MRI,3
 PEG,3
−/−,2
 SPECT,2
 chemotherapy,18
 ATP,2
 mAb,3
 Silibinin,2
 10,3
 oxaliplatin,2
Breast cancer,11
1H,2
 H,2
 meta-analysis,5
 squamous cell carcinoma,7
 endobronchial metastasis,2
 nicotine,2
 hepatocellular carcinoma,5
 immunosurveillance,2
 magnetic resonance imaging,5
 Small cell lung cancer,6
Cytotoxicity,2
 confidence interval,7
 PKC,3
 Colorectal cancer,6
 smoking cessation,2
 propidium iodide,2
 MDR,2
 TNF,3
Epidermal growth factor receptor ,2
 P-glycoprotein,2
 Fine needle aspiration,2
 Internal target volume,2
 Neuroendocrine,2
 Treatment response,2
 quality of life,2
 CT,5
Chemotherapy,10
 VEGF,6
 Palliative care,4
 everolimus,3
 review,5
 personalized therapy,2
 HER2,3
 forced vital capacity,3
 solitary pulmonary nodule,2
 epithelial–mesenchymal transition,2
 CSC,3
Angiogenesis,6
 vitamin D,2
 Review,2
 Urothelial,2
 RT-qPCR,2
 Tumor targeting,2
 Risk factors,3
 AML,2
 Poly,16
 receptor,2
 HWE,2
 Thoracic Surgery,2
 Local recurrence,2
 pulmonary,3
CEA,2
Diaphragm,2
 Épidémiologie,2
FNAC,2
 EPR,2
 Thoracotomy,3
 Natural product,2
 NAC,2
 Lung carcinoma,3
 Synergism,2
 complexes,2
 Minimally invasive surgery,3
 lung neoplasms,8
 spindle assembly checkpoint,2
case-control studies,2
 p53,9
 Low-dose computed tomography,2
 Non-Small-Cell Lung,5
 radiation pneumonitis,3
 Driver mutations,2
DNA methylation,6
Cáncer de pulmón,2
 SATB1,2
 ORF,2
 Nanoparticle,2
 MMPs,2
 miRNA,3
 ovarian cancer,2
 glutathione,2
CIP2A,2
 Quality of Life,2
 Cancer therapy,2
F]fluoropropyl,2
ethylene glycol,2
2-,3
 FVC,3
AKT,3
5-c]quinazolines,2
 early detection of cancer,3
brain metastases,2
 small-cell lung cancer,2
 Oligometastases,3
 adenocarcinoma,13
 histology,2
3-,3
 Non–small cell lung cancer,6
 Toxicity,5
 Hepatocellular carcinoma,4
 Neoplasm metastasis,4
Lung cancer,38
 single nucleotide polymorphism,4
 radiotherapy,10
 IHC,3
 polyethylene glycol,2
 PET/CT,6
 PET-CT,2
 1,4
 MAPK,5
benzamides,2
 Individualized medicine,2
 Non-small-cell lung cancer,12
EBUS,2
 Epidermal Growth Factor,2
computed tomography,2
 Non-small-cell lung carcinoma,5
 MA,2
2-[,3
 prognosis,20
 SKP2,2
Cancer risk,2
 head and neck cancer,2
Immunohistochemistry,3
BAP1,2
 miRNAs,3
 tumor microenvironment,2
 breast cancer,7
 Transcription,2
 prostatic neoplasms,2
Western blot analysis,2
 tumor,2
 Lung segmentectomy,2
 invasion,3
 NMR,2
 FOXP3,2
 Mortality,5
 caspase-3,2
cancer,5
 Small-cell lung cancer,2
 epidermal growth factor receptor mutation,2
 Never smokers,2
 Positron emission tomography ,2
 carcinoembryonic antigen,3
 Survival,11
caprolactone,2
 sorafenib,2
 biomarkers,3
Adjuvant chemotherapy,3
pyrene,2
 standard deviation,3
 small cell lung cancer,11
 Smokers,2
 Endobronchial ultrasound,3
 in vivo imaging,2
 recurrence,2
 Radiosurgery,3
 PI,2
 Images,2
 methylation,2
 epidemiology,2
 Poly[2-,2
 RNA interference,4
 colorectal cancer,8
Bangladesh,2
 Epidermal growth factor receptor ,4
 KRAS,9
 Reference genes,2
 lobectomy,11
Antiproliferative,2
Concurrent chemoradiation,2
VATS,17
 non–small-cell lung cancer,2
 positron emission tomography ,2
 non-small-cell lung cancer,13
 Surgery,20
 sarcoma,2
 risk assessment,2
 Vascular endothelial growth factor,3
Cancer bronchique,2
 lung,24
 H3K27me3,2
 RNA,2
 PM,2
 AUC,3
 Melanoma,6
 RES,2
 prostate,2
 signal transducer and activator of transcription 3,2
 interleukin,3
 Tubulin,2
Endobronchial ultrasound,3
 PAH,2
 chemokines,2
 T helper,2
 senescence,2
 SUV,2
 Free radicals,3
 NSCLC,46
 Resistance,4
 Pulmonary resection,2
 TERT,2
 Radiography,3
 NO,2
 growth,2
 DDR2,2
lung cancer,2
 nonsmall cell lung cancer,4
 p63,2
 Cell proliferation,4
Non-small-cell lung cancer ,2
 Particle therapy,3
 HL-60,2
 5-,2
ALK,8
 RNAi,3
Economics,2
 fatigue,2
 HR,2
 microenvironment,3
 autophagy,4
 Diagnosis,3
 TGF-β,2
 non-small cell lung cancer,54
Bladder cancer,2
 KRAS mutation,2
 shRNA,3
5-FU,2
angiogenesis,2
 expression,2
3H-quinazoline-4-ylidene,2
 CI,7
 tyrosine kinase inhibitor,6
 VATS,3
 stable disease,2
Non-small-cell lung cancer,2
 gefitinib,9
 DAPI,2
 Food and Drug Administration,2
 imaging,4
breast cancer,4
 survivin,3
 IL-10,2
 immunohistochemistry,10
 HCC,4
 Receptor,2
 telomerase reverse transcriptase,2
 TGF,3
 colorectal carcinoma,2
 SCLC,9
 Radiation therapy,3
KRAS,3
Adjuvant therapy,2
 cisplatin,9
 NFκB,4
 cancer treatment,3
 acute myeloid leukemia,2
 targeted treatment,2
 Non-small cell lung cancer,34
Anticancer,4
Anti-cancer,3
 Chemokine ,2
 Lung cancer,102
 Migration,2
 gene amplification,3
AP-1,2
 Drug delivery,2
 metabolism,2
 SD,4
Akt,2
 Multidrug resistance,2
 mediastinal lymph nodes,2
 prodrug,2
 standardized uptake value,2
 MTT,5
C-X-C motif,3
COPD,6
 cancer,24
 genotype,2
 Lung lesions,2
colorectal cancer,3
 osteosarcoma,3
 small cell lung carcinoma,4
 Pancreas,2
 Stereotactic body radiation therapy,2
 Video-assisted thoracic surgery,3
 PEI,2
 Lung Neoplasms,11
 adenosquamous carcinoma,2
 Autophagy,4
 mediastinoscopy,3
 Cancer stem cells,3
 mitomycin,2
 curcumin,2
 Morbidity,2
 Cytotoxic activity,2
 BRAF,3
 SNP,3
 ATBC,2
 RT-PCR,2
A549,3
EGFR,20
 Oncology,2
 Systematic review,2
 PBS,2
 Thoracoscopy,3
 Imaging,4
methacrylamide,2
 overall survival,7
 Function,2
 GAPDH,3
 etoposide,2
 HDAC,4
 Hardy–Weinberg equilibrium,2
 EGFR,16
 positron emission tomography,6
 SOD,2
glutamic acid,2
 Mucinous adenocarcinoma,2
biomarker,3
 non–small cell lung cancer,5
 ,3
 Metastases,3
 Mutation,3
 Docetaxel,2
 Ultrasound,2
 cutaneous metastasis,2
 lung neoplasm,3
 PCR,4
 cell adhesion,2
 Anticancer activity,4
 metastasis,31
 thyroid cancer,2
 receiver operating characteristic,4
18F-FDG,2
 LLC,2
 enhancer of zeste homolog 2,2
 mesothelin,2
 Multi-drug resistance,2
